补肾健骨散治疗膝关节骨关节炎的临床观察附膝关节骨关节炎的治疗进展-中医骨伤科学专业论文.docxVIP

中文摘要 中文摘要 目的：探讨膝关节骨关节炎治疗方法，研究补肾健骨散内服治疗早、中期 KOA 的疗效和作用机制。 方法： 1.临床收集 60 例早中期 KOA 患者，随机分为试验组和对照组各 30 例， 试验组给予补肾健骨散内服治疗，对照组给予口服硫酸氨基葡萄糖胶囊治疗，疗 程 4 周，观测患者的疼痛程度分级、症状和体征积分、膝关节功能评分、中医全 身征候评分和胃肠道不良反应以及全身安全性指标，3 个月后随访。2.回顾和评 价中医学与现代医学关于 KOA 的病因病机以及治疗方法。 结果：(1) 治疗 4 周后两组临床疗效比较，试验组控显率 60.00％，总有效率为 76.67％，对照组控显率 53.33％，总有效率为 63.33％，两组有显著性差异(P＜ 0.05)。(2) 两组治疗后的疼痛程度分级、夜间休息痛、晨僵、肿胀、关节功能及 中医全身症候等评分指标自身及组间比较，差异具有统计学意义(P＜0.05)。(3) 两组在治疗过程中均具有不同程度的胃肠道反应，但差异有统计学意义(P＜ 0.05)。两组治疗前后大小便常规、心电图、肝肾功指标变化自身及组间比较差异 无统计学意义(P＞0.05）。 结论：1.目前 KOA 的治疗目标是缓解疼痛，阻止和延缓疾病的发展及保护关节 的功能，降低伤残率。2.补肾健骨散内服治疗早中期 KOA 能够有效改善疼痛、 晨僵、关节肿胀、关节功能和中医全身症候，延缓病情发展，且胃肠道不良反应 少，具有很好的安全性。有利于患者坚持长期服用，值得推广。 关键词：膝关节；骨关节炎；发病机制；补肾健骨散；临床观察 Abstract Abstract Objective：1. To discuss the treatment of knee osteoarthritis. 2. To study the effect of the treatment and mechanism with traditional Chinese medicine (Bushenjiangu San) to KOA. Methods：1. We Used traditional Chinese medicine (Bushenjiangu San) to treat 30 patients with KOA (the experiment group) and controlled by 30 patients treated with Western medicine Glucosamine Sulfate Capsules (the control group). The therapeutic course is four weeks. After three months, we observe the contents including the degree of the pain, the therapeutic effect of symptom and signs, the mark of knee joint function, the mark of lab and the adverse reaction of gastrointestinal tract (GIT). 2. And we Review and evaluate the arguments about KOA on the part of Chinese and modern medicine. Results：(1) Evaluating therapeutic effect after fourth weeks of treatment: the experiment group apparent efficiency ratio of 60.00% and efficiency ratio of 76.67%, while the control group only had 53.33% and 63.33％ (P0.05). (2) Evaluate the degree of the pain, the presenting symptom, objective sign, the mark of knee joint function and the Chinese physician symptoms, all above objectives have ameliorated comparing with pre-treatment in two groups respectively and two groups during treatment, the experiment group provided efficac